Scientific Program

Conference Series Ltd invites all the participants across the globe to attend World Heart Rhythm Conference Istanbul, Turkey.

Day 2 :

Keynote Forum

Cetin Erol

Ankara University, Turkey

Keynote: Echocardiography guided closure of left atrial appandage

Time : 10:00-11:00

Conference Series Heart Rhythm 2018 International Conference Keynote Speaker Cetin Erol  photo
Biography:

Cetin Erol is the Professor of Cardiology in the Cardiology Department at Ä°bn-i Sina Hospital, Ankara, Turkey. He is the Head of the Cardiology Department and Head of the Dept. of Medical Sciences(2003-2012) , Board member of EAE (National Societies Committee (2004-2006), Credential Committee member (20062008), Research and Training Grant Committee member (2006-2008), President of Turkish Society of Cardiology (2006-2010), President of Turkic World of Cardiology Association(2008-2012), Member of the ESC Nominating Committee (2008-2010), Research and Training Grant Committee member (2010-2012), Member of the Committee for Practice Guidelines(ESC) (2012-2014), Member of The Higher Education Council for Turkey 2013-2017, Councillor of the ESC Board (2014-2016). He was honoured with FESC in 1996, Research award for Behçet’s Disease from The Turkısh Scientific and Technical Research Association in 2000, FACC in 2001, Member of ASE in 2002.

 

Abstract:

Atrial fibrillation is a major arrhythmia,which has as high prevalence
among populaion and the risk of stroke increasesgradually by
increasing age.Thromboembolism typically arises from a clot in left atrial appendix (LAA).Oral anticoagulation,surgical occlusion of the LAA and occlusion of LAA using less invasive percutaneous ,catheter based methods are the choices for preventing stroke.This presentation will focus on the LAA closure by percutaneous method.
 

Break: Networking & Refreshments 11:00-11:30 @ Foyer
  • Angiography and Interventional Cardiology | Vascular Surgery | Cardiovascular Medicine | Arrhythmias | Cardio-Oncology | Clinical Cardiology | Cardiac Surgery
Location: Akdeniz 3
Biography:

Taner Åžeker is cardiologist interested in intervetional cardiology. He is a member of Europian Sociaty of Cardiology and Turkish Sociaty of Cardiology. He contributes abstracts or cases regularly for international and national congress.
 

Abstract:

Background: Most patients with ST elevation myocardial infarction (STEMI) have critical multivessel disease that requiring a second intervention. The optimal timing of secondary intervention is not clear. In this study, we aimed to investigate MACE rate regarding the type of secondary procedure to non-infarct related critical lesions in patients with STEMI and critical multi vessel disease.

Methods: A total of 212 consecutive patients with STEMI and critical multi vessel disease had been included in our study. Patients were divided into two groups according to occurrence of MACE. Primary PCI data were collected. Pre and post intervention coronary blood flow and complications were recorded. MACE data of patients were evaluated before discharge, after 3 and 9 months.

Results: A second coronary angiography was performed 132 (62.3%) of STEMI patients in 90 day after primer PCI. The non- infarct related lesions in 26 of 132 patients who underwent second coronary angiography were evaluated non-critically and decided to follow with medical treatment. Secondary PCI was performed 89 of 132 and 17 of 132 patients underwent CABG operation. Patients were divided into two groups according to MACE occurrence. Mean time interval to PCI was significantly lower in patients with MACE (p=0.028). EF (p=0.59) and rate of patients who underwent CABG (p=0.108) were lower, syntax score (p=0.55) and CAD history (p=0.056) were higher in patients with MACE; but there was no statistical significance. The cut-off value of time interval to PCI obtained by ROC curve analysis was 16,5 days for prediction of MACE in 9 months (sensitivity: 75.0%, specificity: 69.2%). The area under the curve (AUC) was 0.680 (p=0.039) (Figure-1).

Conclusion: Late PCI or CABG can be thought to be the optimal strategy for patients with STEMI and multivessel disease. 

Speaker
Biography:

Abstract:

Introduction: Left ventricular assist device (LVAD) therapy can improve mortality and quality of life in patients with end-stage heart failure who are either waiting for or not a candidate for cardiac transplantation. 1 LVAD therapy is associated with significant complication and comorbidity including; device infection, bleeding, thrombus, stroke, and mechanical failure. 2 Patients with chronic heart failure have a high incidence of the major depressive disorder, which has been shown to negatively affect outcomes in patients being treated with medical therapy. 3 This study was designed to evaluate the relationship between LVAD driveline infection and depression.
 
Methods: After our study was approved by our local Institutional Review Board, we evaluated all left ventricular assist device patients who were implanted between January 2016 and November of 2017 who were implanted at Community Regional Medical Center and who underwent screening for depression with the Patient Health Questionnaire (PHQ) 9 prior to implantation. Chart review was performed to identify those patients with a documented history of driveline infection which was defined by either a positive culture from the driveline exit site or documentation of an infection which led to the use of antibiotics. Kaplan Meyer event-free survival curves were generated and the difference between the two curves was analyzed using the log-rank test. (Figure 1)
 
Results: Twenty-three patients were identified during the time period in question who met our inclusion criteria. 10 patients developed a driveline infection during the time in question. Of the 10 patients who developed a driveline infection, 9 patients had score ≥ 5 on the PHQ-9 score indicating possible depression, while only 1 patient who scored < 5 had documented driveline infection (HR 5.3391, 95% confidence intervals 1.407 to 20.257, P = 0.064). Meantime to development of a driveline infection was 49 months in the PHQ < 5 group as compared to 35 months in the PHQ ≥ 5 group.
 
Conclusion: Depression, as indicated by a score of ≥ 5 on the PHQ 9 score, does significantly predict driveline infections. Our data did show a strong signal and was likely underpowered to detect a significant difference during our observation period. Further testing using a larger sample size may provide a more definitive answer to the relationship between the driveline exit site infections and depression.

Agata W Dżeljilji

National Tuberculosis and Lung Diseases Research Institute, Poland

Title: Alpha-1 antitrypsin deficiency (AATD) as a risk factor of aortic aneurysm- Is it still actual?

Time : 13:00-13:30

Biography:

Agata W Dżeljilji is a practicing surgeon at the Institute of Tuberculosis and Lung Disease in Warsaw, where she is studying management of thoracic disease. She
conducts research in pulmonology and vascular surgery. Her main clinical intrests are metabolic aspects of elastin and collagen fibers proteolysis in the diseases
of the respiratory and vascular system, and the significance of alpha-1 antitrypsin deficiency. Her most recent publication is 'The role of alpha-1-antitrypsin protein
in the pathogenesis of aortic aneurysm'. She is also a reviewer for JTD.

Abstract:

Alpha-1-antitrypsin is a potent antiprotease playing an important role in maintaining protease-antiprotease balance. It protects the structures of extracellular matrix against destruction by proteolytic enzymes. Loss of elasticity occurs when increased protease activity is accompanied by qualitative impairment or reduced con- centrations of antiproteases. Alpha-1-antitrypsin de ciency is a risk factor for obstructive lung disease, including emphysema, liver and kidney disorders and, less often, follicular panniculitis, granulomatosis with polyangiitis (previously Wegener’s granulomatosis). Literature also emphasises the role of AAT in the development of aortic aneurysms, and results of biochemical studies support this theory. Aortic aneurysm is an important clinical problem, unceasingly associated with high mortality. For this reason, it is exceptionally important to identify its risk factors. Studies on the relationship between AAT and development of AAA (abdominal aortic aneurysm) have been conducted since the 1990s. Due to the development in molecular diagnostic techniques, new reports on the topic appeared over the last decade.

Break: Lunch Break 13:30-14:30 @ Daphe Restaurant
Biography:

Abstract:

Background: Fatal ventricular arrhythmias, including serious ventricular tachycardia (VT) and ventricular fibrillation (VF), have been reported to occur in 1–5% of the patients undergoing primary coronary angioplasty. These events may cause hemodynamicaly instability and affect procedure outcome.
Objectives: To assess effect of Intravascular Metoprolol administration to prevent fatal arrhythmias in patients of STEMI undergoing Primary Percutaneous coronary angioplasty
Methods: An open, randomized study was carried out at single centre to treat 220 patients who had undergone primary PCI for STEMI. The patients were randomized to either receive IV metoprolol 15 mg(110 subjects) or not to receive the medication(110 subjects) prior to procedure . The outcomes were the detection of arrhythmias before ,during procedure and
post 12 hours of PCI.
Results: Number of patients with normal sinus rhythm was significantly higher (p <0.001) in treatment group (47.27%) when compared to control group (24.45%). Incidence of fatal arrhythmias was lower in treatment group (6.36%) but it was statistically insignificant (p>0.05).
Conclusion: Metoprolol lowers the incidence of fatal arrhythmias in patients undergoing primary PCI. More large scale studies
are required to establish its definitive role in prevention of fatal arrhythmias during primary PCI

Speaker
Biography:

Pervaiz Chaudry is Working as Co. Chairman& Programme Director at Cardiac Surgery Department, National Institute of Cardiovascular Surgery NICVD, Karachi. He is a pioneer of Heart Failure Programme and Minimally Invasive Surgeries at this institute. Currently, 13 residents and 4 fellows are under his training. He is doing all heart surgeries minimally invasive including LVAD, Multi-vessel CABG, all Valves, CABG Valves, Adult Congenital Heart Surgery, and multiple time redo procedures. He is traveling entire country to teach all procedures and make them in working. His efforts are to “Never Say No to any Patient”.

Abstract:

Introduction: Minimally invasive double valve replacement (DVR) surgery through a small transverse anterior thoracotomy is an alternate technique than sternotomy for concomitant aortic and mitral valve (AVR, MVR)surgery that
can reduce surgical stress and length of hospital stay. Endoscopy and robot-assisted surgery is being practised in developed countries but its technically very difficult, time-consuming, costly and not reproducible by all surgeons. As median sternotomy is preferred approach for DVR, therefore, we aimed to introduce direct vision minimal invasive DVR (DVMI-DVR) to the surgeons in our setting for common public.
 
Objectives: Aim of this research was to evaluate the in hospital and early outcomes of direct vision minimal invasive double valve surgery at a tertiary care cardiac centre of a developing country.
 
Patients And Methods: This prospective observation study was conducted at National Institute of Cardiovascular Diseases Karachi, Pakistan from January 2018 to September 2018. 19 consecutive patients undergoing DVMI-DVR for aortic and mitral disease without any prior cardiac surgery were included in this study. For all procedures access was through small transverse anterior thoracotomy incision with wedge resection (Chaudhry’s Wedge) of sternum opposite to 3rdand 4thcosto-sternal joints. Patients were observed during hospital stay and were followed to observe length of hospital stay(LOHS), ventilatory support, pain score, and mortality. Data were entered and analysed using SPSS version 23.
 
Results: The male/female ratio was 11:8 with mean age of 35± 12 years.Mean total bypass time was 129.8 ± 23.83 min (range 98-181 mins).Mean mechanical ventilation time was 3.16± 1.12 h (range 2–6 h). Mean post operative LOHS was 5.63 ± 1.12 days (range 4–8 days). We had zero surgical mortality. Mean pain score of 4.32 (on predefined pain scale of 1 to 9 with high
value indicating severe pain).
 
Conclusions: Minimally Invasive DVR surgery is a safe and reproducible technique with the acceptable surgical outcome. It carries good post-operative recovery, patient’s satisfaction and early return to daily activity.

  • Heart Disease and Failure | Heart Device | Pediatric and Geriatric Cardiology | Case Reports In Cardiology | Neuro-Cardiology | Hypertension | Heart Device | Cardiology-Future Medicine
Location: Akdeniz 3

Session Introduction

Waheib A Bamatraf

Saud Al-Babtain Cardiac Center, Saudi Arabia

Title: Case report of Ivabradine use post acute MI complicated by cardiogenic shock and review of literature

Time : 11:30-12:00

Speaker
Biography:

Waheib A Bamatraf is a cardiologist at Saud Al-Babtain Cardiac center in Dammam, Saudi Arabia. He has a passion for patient care as a whole human being rather than a diagnosis, enjoys research and believes that learning is an endless process.

Abstract:

Background: The cornerstone of the management of cardiogenic shock (CS) is
inotropic agents. However, they have a drawback of increasing heart rate (HR) which is considered an independent predictor of mortality. Ivabradine has a potential of reducing HR without interfering with positive effects of inotropes.
Case: A 37 years old man known case of DM, presented with extensive anterior STEMI. Primary PCI was done to LAD. During the procedure he developed recurrent VF for which DC shocks were given, CPR was done for 4 minutes. He was started on mechanical ventilation. Subsequently IABP was inserted along with introduction of Dopamine, Noradrenaline and Adrenaline at maximum doses. Post intervention his systolic blood pressure (SBP) was between 90-100 mmHg and HR was 125-140 bpm and tissue hypoperfusion was evident. Echo showed LVEF 35% with no mechanical complications. After 24 hours from admission, due to significant tachycardia, Ivabradine was initiated. The next day, significant improvement in HR 80-100 bpm and improvement in SBP 110-120 mmHg were noted; which allowed discontinuation of inotropes and extraction of IABP. He was discharged from the hospital after 6 days of admission. No adverse effects were documented during hospitalization.
Discussion: The pharmacological management of CS has not evolved for long time. It is hampered by difficulty in conducting RCTs in such critical unstable patients. Ivabradine is currently not used in CS due to lack of supporting evidence, despite that sound understanding of physiological and pharmacological aspects of CS and inotropes favors a possible role for controlling heart rate without negative inotropy.
Conclusion: Concomitant use of Ivabradine with maximal inotropes didn’t result in adverse effects, actually, favorable hemodynamics were noted within 24 hours of initiation in our single case reported here. Further research may be warranted to explore feasibility of Ivabradine use in such clinical setting.

Sekib Sokolovic

University Clinical Center Sarajevo, Bosnia and Herzegovina

Title: Ajmalin is a drug of choice in paroxisimal tachycardia

Time : 12:00-12:30

Speaker
Biography:

Sekib Sokolovac is the Head of the Governmental Organization in Bosnia and Herzegovina. He is graduated from Medical Faculty Sarajevo in 1983. He is awarded as the specialist in Internal Medicine in 1994. He has done Master of Science in 1998. He was awarded PhD in 2004. Mr.Sokolovac is a fellow of University California Irvine, Oxford, AKH Vienna. He is specialist in both Cardiology and Rheumatology. He had started working in University Clinical Center Sarajevo from 1990 in the Department of Cardiology. He is the Director of Excellence Center for Arterial Hypertension. Vice-President of the Association of Cardiologists of Bosnia and Herzegovina, ESC Nucleus Member of Working Group on Pulmonary Circulation and Right Heart, President of the Working Group on Arterial Hypertension of UKBiH and He served as the Editorial Board Member of Rheumatology International Journal, European Journal of Rheumatology, Mediterranean Journal of Rheumatology. He had published many papers and books. He also have done many research projects in his field.

Abstract:

Introduction: Ajmalin is a class Ia antiarrythmic agent that blocks the sodium ion channels. This agent is mainly used in detecting Brugada syndrome, but also it has effects on prolonging the action potentials and provoking the lenghtening of the QT interval. The final result is in the slowing of the heart beat.
Material and Methods: This case report showing paroxismal supraventricular
tachycardia in a 55y/o male patient who suffered from myocardial infarction one month ago. The patient received i.v. and oral beta blockers, Ca-channel antagonists, Propafenone, Amiodarone,Xylocain , sotalol, 2grams of Magnesium i.v. There was no
efficiancy, except the minimum one with magnesium that slowed the heart rate from 160 per minute to 130/min.
Result: ECG after i.v. bolus of 50mg/10ml of ajmalin.
 
Conclusion: This is the great example of our expirience with ajmalin in a treatment of paroxismal tachycardia. We have been using ajmalin with a great efficiacy for more than 25 years or so. We recommend to all practitioners to consider using this very efficient antiarrhythmic drug.

Speaker
Biography:

Abdullah Orhan DemirtaÅŸ has completed his MD at the age of 30 years from Health Science University Adana Health Practise and Research Center. He is the
resident doctor of Health Science University Adana Health Practise and Research Center. He has published more than 5 papers in reputed journals and has been
serving as an editorial board member of repute.

Abstract:

Purpose: Recently, a significant increase in the frequency of the usage of cardiac implantable electronic devices (CIED) in cardiology. Pneumothorax (PTX) is one of the most important complications that is met while placing CEID. There is not a distinct data that is shown between body mass index (BMI) and clavicle length in the patients with PTX. In our particular study, we aim to investigate if there is a relationship between PTX and clavicle length and BMI in the patients with CIED.
 
Method: We included 1702 patients who had been placed CIED for any reason retrospectively between the years 2008 and 2018. We recorded demographic and procedural data in addition to clavicle length and BMI/clavicle length (PTX index).
 
Findings: We included 1568 patients without PTX and 34 (2.2 %) patients with PTX in our study. When anatomical distances were compared, it was found that clavicle proximal distal, angulus mandibular clavicle middle region, angulus mandibular clavicle distal tip distances decreased significantly in patients with PTX and PTX index increased significantly. The distance
between angulus mandibular clavicle tip (OR:0.811) and pneumothorax index (OR:8.014) were determined as the variables for pneumothorax. When the cut-off value for PTX index was taken as 1.67, it was observed that PTX was predicted with 70 % sensitivity and 62 % specificity.
 
Result: The length of clavicle and BMI can provide the operator with prognosis about the PTX development in the patient.

Break: Lunch Break 13:00-14:00 @ Daphe Restaurant

Armin Attar

Shiraz University of Medical Sciences, Iran

Title: Cardiovascular risk based intensive blood pressure reduction

Time : 14:00-14:30

Speaker
Biography:

Armin Attar is an interventional cardiologist from Shiraz University of Medical Sciences. He has founded Traditional and Advanced Heart Approaches (TAHA)
clinical trial group and have guided several investigations in the field of primary prevention of cardiovascular diseases. He has also a Ph.D. on stem cell biology
and technology and his main focus of research is mesenchymal stem cells in that field.

Abstract:

Statement of the Problem: In the new ACC/AHA hypertension guidelines,
individualized cardiovascular risk assessment is emphasized and aggressive
management of blood pressure using a 10-year risk of cardiovascular events of
more than 10% is recommended. However, this decision is being criticized as
not being based on a trial results. Methodology & Theoretical Orientation: To
perform a secondary analysis, we obtained the data of Systolic Blood Pressure
Intervention Trial (SPRINT) from NHLBI Data Repository Center. In SPRINT,
an open-label trial, non-diabetic participants with SBP of ≥130 mmHg were
randomized to intensive and standard treatment groups with SBP targets of <120 and <140mmHg respectively. The primary composite outcome was myocardial infarction, and other acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes. Here, we have analyzed data from participants without CVD and chronic kidney disease aged below 75 years categorized based on baseline 10 years Framingham cardiovascular (<10% [low risk]; ≥10 [intermediate or high risk].
 
Findings: A total of 4298 patients were included in the analysis. Throughout the 3.12 years of follow-up, the mean SBP level was 122.76±8.19 and 135.31±6.48 mmHg in the intensive and standard treatment groups, respectively (average difference, 12.55 mmHg; P< 0.001). In general, patients with a risk above 10% showed a significant benefit (HR with intensive treatment, 0.43; 95% CI, 0.28 to 0.66; P< 0.001). As is shown in the Figure this benefit was not affected by sex, age, BP level, race, and consumption of aspirin or statins. However, intensive BP reduction was not useful for those at low risk (0.75% per year vs. 0.57% per year; HR, 1.14; 95% CI, 0.55 to 2.38; P=0.714).
 
Conclusion & Significance: Intensive SBP reduction is beneficial for primary prevention of cardiovascular morbidity and mortality in non-diabetic patients with more than low cardiac risk (above 10%).

Sawsan Al Yousef

CRESENT, King Fahad Medical City, Saudi Arabia

Title: Medical simulation training and heart rhythm identification

Time : 14:30-15:00

Biography:

Sawsan Al Yousef, MD, CABP, FCCP, Assistant Professor king Saud Bin Abdulaziz University and Health Science, Clinical and Research Pediatric Critical Care fellowship from University of Western Ontario, Canada, 2001, Clinical Pediatric Respiratory, University of Toronto, Canada, Arab and Saudi Board of Pediatrics, 1997.Currently Appointed as Consultant Pediatric Intensive Care and Pulmonory at King Fahad Medical City(KFMC) ,Chairperson of Post Graduate simulation department at Center for research , Education, Simulation enhance training CRESENT)KFMC, Director of Saudi Commissioner for Health specialty for PICUFellowship Examination committee, Saudi Arabia.

Abstract:

Simulation is a technique to replace or amplify real experiences in an interactive setting. Simulation-based learning (SBL) applies this, through the use of role play, simulated patients, part-task trainers, virtual reality devices and electronic manikins. Patient safety priorities are at the forefront of health providers' concerns and this has driven a more consultant-led service. The see one, do one, teach one philosophy has hopefully been and certainly should be, eliminated. SBL can take place without exposing patients to risk, at the speed of the learner, with immediate feedback and the ability to adapt to the learner in a completely flexible way. Perhaps this is best summarized by saying that simulators have the potential to take the early and dangerous part of the learning curve away from patients. Benefits of medical simulation includes safe environment, mistake forgiving, trainee focused vs. patient focused, controlled, structured, proactive clinical exposure, reproducible, standardized, debriefing, deliberate and repetitive practice. Simulation has rapidly evolved as a learning tool and technology over the past 15 years, and has been shown to be an effective method for teaching. Despite this, the field of cardiovascular medicine is still in the primitive stages of adopting simulation. The reasons cited for this include: the high cost of simulators, a dearth of didactic curricula to accompany the psychomotor skill learned on a simulation, the wide variability and/or lack of consistency that exists among the simulation platforms, and a complete absence of large trials showing that this expensive technology actually improves operators' skill in the angiography suite and presumably enhances patient outcomes. Despite all this, the ACGME now mandates that cardiovascular fellowship training programs must have simulation as part of fellow training. Cardiac simulation training ranges from as simple as training on listening to normal and abnormal heart sounds, differentiating different types of heart murmurs, interpreting ECG findings, utilizing high fidelity manikins for different cardiac scenarios such as heart failure and cardiogenic shock apply team work as crew resource management, practicing transthoracic echocardiogram plus transoesophegeal echo (TEE), cardiac catheterization and central line insertion up to different cardiac interventional procedures. On June 2017- May 2018, we conducted once per month a one day simulation cardiac course for pediatric residents whom had attended different simulation courses at CRESENT, KFMC. All candidates went through pre course knowledge and clinical skills evaluation followed by the end of the day with post course knowledge and clinical skills evaluation similar to the pre course.125 candidates were involved, 100% of the candidates had significant improvement in their knowledge and skills at post course test compared to pre course and non had declined in their scores beside 100% of them found these courses are enjoyable, safe, not stressful and very useful training methods, 97% enjoyed it mostly because it is repetitive and mistakes are forgiven with zero hazards to patients.100% feels video debriefment following cardiac medical scenarios is very helpful asit clarify areas for improvement much better than conventional training. In conclusion, although cardiac Simulation courses is expensive but it plays important role in patient safety expensive but it plays important role in patient safety so at the end it is cost effective so would encourage to make it mandatory in the curriculum for cardiac residents and fellows.

  • Workshop
Location: Akdeniz 3

Session Introduction

Marc Ghannoum

University of Montreal, Canada

Title: Hemodialysis and hemoperfusion for treatment of poisoning to cardio toxic drugs
Speaker
Biography:

Marc Ghannoum is an internist and nephrologist from Montreal Canada. He currently chairs the EXTRIP workgroup and has published over 50 papers and 10 book chapters on the subject of extracorporeal removal of poisons.

 

Abstract:

Historically, the clinical application of extracorporeal treatments (ECTRs), such as hemodialysis or hemoperfusion, was first intended for poisoned patients. With time, ECTRs were used almost indiscriminately to facilitate the elimination of many poisons, albeit with uncertain clinical benefit. To determine the precise role of ECTRs in poisoning situations, multiple variables need to be considered including a careful risk assessment, the poison's characteristics including toxicokinetics, alternative treatments, the patient's clinical status, and intricacies of available ECTRs, all of which are reviewed in this article. Recently, evidence-based and expert opinion-based recommendations from the EXTRIP workgroup were also published to help minimize the knowledge gap in this area. Here, we will present current systematic reviews and guidelines from the EXTRIP (EXtracorporeal TReatments In Poisonings) workgroup where we discuss potential cardiotoxic drugs such as Digoxin, Tricyclic antidepressants, Carbamazepine.

Break: Lunch Break 12:30-13:30 @ Daphe Restaurant